Business Context and Reporting Period
This Form 8-K, dated April 21, 2022, reports that LMF Acquisition Opportunities, Inc. ("LMAO"), a special purpose acquisition company (SPAC), entered into a definitive Merger Agreement with SeaStar Medical, Inc. ("SeaStar Medical"). The transaction involves a business combination where LMAO will acquire SeaStar Medical, a medical device company, through a merger with a wholly-owned subsidiary. The filing details the terms of the merger, related agreements, and conditions precedent to closing.
Key Financial Metrics and Transaction Terms
- Merger Consideration: The aggregate consideration for SeaStar Medical stockholders is $85,000,000, payable solely in LMAO common stock valued at $10.00 per share.
- Adjustments: The consideration is subject to deductions for SeaStar Medical indebtedness and transaction expenses exceeding $800,000 (the "Cap").
- Equity Treatment: Outstanding SeaStar Medical convertible notes and preferred stock will convert to common stock prior to the merger. Existing warrants, options, and restricted stock units will be assumed by LMAO and converted into equivalent LMAO instruments.
- Liquidity Condition: Closing requires LMAO to have at least $15,000,000 in unrestricted cash on hand, inclusive of proceeds from a private investment in public equity (PIPE) and net of redemptions and expenses.
- Net Tangible Assets: LMAO must maintain net tangible assets of at least $5,000,001 at closing.
- PIPE Commitment: Dow Employees' Pension Plan Trust and Union Carbide Employees' Pension Plan have committed to purchase at least $5,000,000 of LMAO common stock in a PIPE transaction contingent on the closing.
Material Changes and Conditions
The primary material change is the execution of the Merger Agreement, transitioning LMAO from a SPAC seeking a target to a company with a definitive business combination. The transaction is subject to several critical conditions:
- Approval by stockholders of both LMAO and SeaStar Medical.
- Nasdaq listing approval for the post-combination common stock.
- Satisfaction of the minimum cash and net tangible asset thresholds.
- Termination rights exist if the closing does not occur by July 29, 2022, or October 29, 2022 (if extended by the Sponsor depositing $1,035,000).
Guidance, Risks, and Management Commentary
The filing contains forward-looking statements regarding the anticipated benefits, timing, and valuation of the business combination. Management highlights significant risks that could prevent the transaction from closing or affect future performance:
- Transaction Risk: Failure to obtain stockholder approval, satisfy cash conditions, or meet the business combination deadline.
- Operational Risk: SeaStar Medical may never achieve or sustain profitability and may require additional capital.
- Regulatory Risk: Potential delays or failure to obtain regulatory approval for SeaStar Medical's products.
- Market Risk: Risks related to the competitive medical device industry and the ability to retain key employees.
- Lock-up Agreements: The Sponsor and certain SeaStar Medical stockholders have agreed to lock-up periods, generally 12 months post-closing or until the stock price exceeds $12.00 for 20 trading days within a 30-day period.
Investor Verification Checklist
- Verify the final valuation of SeaStar Medical after accounting for any debt deductions and transaction expense caps.
- Confirm the final amount of cash remaining in the trust account after public stockholder redemptions and the completion of the PIPE financing.
- Monitor the status of stockholder approval votes for both LMAO and SeaStar Medical.
- Review the definitive proxy statement/prospectus (Form S-4) for detailed risk factors and SeaStar Medical's financial history.
- Track the extension deadline (July 29, 2022) and whether the Sponsor deposits the required funds to extend the closing period.